重庆市药品监督管理局关于中药材GAP符合性信息的通告 根据《国家药监局 农业农村部 国家林草局 国家中医药局关于发布〈中药材生产质量管理规范〉的公告》（2022年第22号）和《重庆市药品监督管理局实施 中药材生产质量管理规范工作指导原则》（渝药监〔2023〕36号）精神，太极集团重庆桐君阁药厂有限公司对其甘草药材供应商内蒙古塞外朔漠中药材有限 公司（合作方：重庆中药材有限公司）开展了审核检查，认为符合GAP要求。我局对太极集团重庆桐君阁药厂有限公司的GAP自评材料进行了审核，符合要 求，现予通告。 中药材GAP符合性信息 | 药品生产企业 | 中成药/饮片 | 中药 材 | 中药材种植 | | 基地面积 | 检 查 | | --- | --- | --- | --- | --- | --- | --- | | 名称 | 品种 | 品种 | 企业 | 基地地址 | （亩） | 结 | | | | | | | | 果 | | | 沉香化气片 | | | | | | | | 四君子合剂 | | | | | | | | 桔贝合剂 | | | | | | | | 龙胆泻肝片 | | | | | | | | 黄连上清丸 ...

Core Insights - The eighth "Belt and Road" Traditional Chinese Medicine Development Forum and the third OTC Brand Conference will be held in Hangzhou from November 24 to 26, 2025, focusing on the internationalization of traditional Chinese medicine, brand building, and industrial innovation paths [1] Group 1: Company Overview - China National Pharmaceutical Group (China National Pharmaceutical Tai Chi) is a leading enterprise in the traditional Chinese medicine industry, invited to present at the conference with a speech titled "Tai Chi IP: From Chinese Corporate Symbol to Global Health Symbol" [3] - The company has accumulated significant brand assets, including three century-old enterprises, two time-honored brands, six items of intangible cultural heritage, and 1,317 registered trademarks domestically and internationally [4] Group 2: Brand Development Strategy - The company aims to transform "Tai Chi IP" into a unique global health symbol through a systematic strategy involving brand strategy, culture, recognition, communication, experience, and management [7] - The strategic path includes establishing a differentiated communication matrix for the mother brand, sub-brands, and a "4+1 pipeline" brand to promote a nationwide Tai Chi fashion trend [7] Group 3: International Expansion - As one of the "National Traditional Chinese Medicine Service Export Bases," the company has upgraded from "product export" to "service and model export," with over 30 product specifications entering more than 20 countries and regions, achieving nearly 100 overseas registration numbers and doubling export sales [8] - The company plans to build an international technological innovation system tailored to traditional Chinese medicine, integrating traditional theories and modern clinical efficacy to promote Tai Chi culture globally [8] Group 4: Awards and Recognition - At the conference, the company received multiple honors, with its core products ranking first in various categories of the "2025 Annual Comprehensive Statistics Ranking of Non-Prescription Drug Products" [8] - The company aims to continue promoting high-quality development in the traditional Chinese medicine industry, aspiring for "Tai Chi IP" to become a health symbol connecting tradition with modernity and China with the world [10]